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Karyotype complexity and prognosis in acute myeloid
leukemia
F Stölzel1,15, B Mohr1,15, M Kramer1, U Oelschlägel1, T Bochtler2, WE Berdel3, M Kaufmann4, CD Baldus5, K Schäfer-Eckart6,
R Stuhlmann7, H Einsele8, SW Krause9, H Serve10, M Hänel11, R Herbst11, A Neubauer12, K Sohlbach12, J Mayer13, JM Middeke1,
U Platzbecker1, M Schaich14, A Krämer2, C Röllig1, J Schetelig1, M Bornhäuser1 and G Ehninger1
A complex aberrant karyotype consisting of multiple unrelated cytogenetic abnormalities is associated with poor prognosis in
patients with acute myeloid leukemia (AML). The European Leukemia Net classiﬁcation and the UK Medical Research Council
recommendation provide prognostic categories that differ in the deﬁnition of unbalanced aberrations as well as the number
of single aberrations. The aim of this study on 3526 AML patients was to redeﬁne and validate a cutoff for karyotype complexity
in AML with regard to adverse prognosis. Our study demonstrated that (1) patients with a pure hyperdiploid karyotype have
an adverse risk irrespective of the number of chromosomal gains, (2) patients with translocation t(9;11)(p2122;q23) have an
intermediate risk independent of the number of additional aberrations, (3) patients with ⩾ 4 abnormalities have an adverse risk
per se and (4) patients with three aberrations in the absence of abnormalities of strong inﬂuence (hyperdiploid karyotype, t(9;11)
(p2122;q23), CBF-AML, unique adverse-risk aberrations) have borderline intermediate/adverse risk with a reduced overall survival
compared with patients with a normal karyotype.
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INTRODUCTION
The term complex aberrant is designated to describe karyotypes
with multiple unrelated cytogenetic abnormalities. In acute
myeloid leukemia (AML), 10–14% of all AML patients, and up to
23% among older AML patients, have karyotypes with ⩾ 3
aberrations.1–4 These karyotypes with ⩾ 3 aberrations are classiﬁed
as adverse genetic risk according to the recommendations of the
European Leukemia Net (ELN).1 However, the UK National Cancer
Research Institute Adult Leukaemia Working Group (abbreviated
as MRC for Medical Research Council) classiﬁcation requires ⩾ 4
abnormalities as an informative cutoff for adverse prognosis.5
Beyond the 3 vs 4 cutoff discordance, the impact of the so-called
pure hyperdiploid karyotype (HDK) without structural aberrations
or monosomies has not been addressed conclusively.6,7 Further
complicating, the deﬁnition of unique adverse-risk abnormalities,
which deﬁne adverse risk per se, is not fully congruent in both
classiﬁcation systems, with some abnormalities conferring adverse
risk according to the ELN but not the MRC and vice versa. Given
this heterogeneity, further exploration of complexity seems
desirable for several reasons. First, it has been demonstrated that
in the adverse-risk group, some patients with certain chromoso-
mal abnormalities fare even worse than others when receiving
standard treatment regimens for adverse-risk patients.8–12 Second,
better individual risk prognostication and uniformly deﬁned
adverse-risk group allocation are required in order to homo-
geneously compare treatment regimens at different institutions.
The aim of this study was to deﬁne the optimized cutoff of
complexity in adult AML in the context of the number of unrelated
aberrations (3 vs ⩾ 4) as well as to deﬁne the impact of the pure
HDK within these groups. Therefore, we evaluated the survival of
417 intensively treated adult non-APL and non CBF-AML patients
with complex aberrant karyotypes out of 3526 AML patients who
were included in three prospective, randomized, multicenter
treatment trials of the Study Alliance Leukemia.
PATIENTS AND METHODS
Patient population
The databases of three prospective, randomized trials of the Study Alliance
Leukemia, which enrolled a total of 3526 non-APL, intensively treated AML
patients between February 1996 and November 2009, were reviewed for
patients with multiple cytogenetic aberrations (⩾3) as well as normal
karyotype (NK as a control group). The studies were approved by the
institutional review boards of all participating centers of the Study Alliance
Leukemia in agreement with the Declaration of Helsinki and registered
with the National Clinical Trial numbers 00180115 (AML96 trial), 00180102
(AML2003 trial) and 00180167 (AML60+ trial). Written informed consent
had been obtained from each patient.
At diagnosis, chromosome analyses were performed on bone marrow
and/or peripheral blood samples using standard techniques, including
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short-term cultures as reported recently.13 Karyotype description was
performed in accordance with the International System for Human
Cytogenetic Nomenclature criteria.14 According to the deﬁnition of the
MRC, a balanced translocation, for example, t(8;21)(q22;q22), was deﬁned
as a single abnormality, because the two breaks and fusions lead to one
active chimeric fusion protein. A balanced translocation involving more
than two chromosomes was also regarded as a single abnormality.
Trisomies or monosomies were regarded as single abnormalities, whereas
the gain of two chromosomes, even if they were identical (e.g., tetrasomy 8),
was regarded as two abnormalities. Unbalanced translocations leading to
gain and loss of chromosomal material were counted as two abnormalities.5
For instance, a derivative chromosome der(7)t(1;7)(q21;q22) is characterized
by a partial monosomy 7q as well as a partial trisomy 1q. In this manner,
an isochromosome i(17)(q10) results in two aberrations, that is, monosomy
17p and trisomy 17q. The monosomal karyotype (MK) was deﬁned by
the presence of two or more distinct autosomal chromosome monosomies
or a single autosomal chromosome monosomy in the presence of one
or more structural chromosomal abnormalities.8
Cytogenetic deﬁnitions
Out of the 3526 patients, a total of 2007 patients with either a complex
karyotype or a normal karyotype were identiﬁed for further analyses
(n=1590 patients with NK; n= 417 patients with ⩾ 3 aberrations which
accounted for 30% of the patients in the AML96 trial and 29% of the
patients in the AML2003/60+ trials—referring to those patients for whom
an aberrant karyotype was diagnosed). Patient characteristics are
summarized in Tables 1A and B. The median follow-up time for all
patients was 6.2 years (interquartile range, 4.5–8 years). Core-binding
factor AML patients (CBF-AML, t(8;21)(q22;q22), inv(16)(p13q22), t(16;16)
(p13:q22)) were excluded since additional chromosomal abnormalities
even if they resulted in complex aberrant karyotypes have no or little
impact on the outcome of patients with favorable-risk CBF-AML5 and could
be conﬁrmed with our CBF-AML patients.11,15 However, previous results
demonstrated an independent inﬂuence of the pure HDK on patients’
outcome worsening overall survival (OS) and event-free survival
signiﬁcantly.15 The scoring criterion for pure HDK performed in our
analyses was deﬁned by (i) gains of whole chromosomes (e.g., trisomies,
tetrasomies), (ii) no additional structural aberrations and (iii) no
monosomies.
The following distinct cytogenetic features were included as possible
candidates of strong inﬂuence: (I) three or four unrelated aberrations,
(II) speciﬁc adverse-risk aberrations that induce an adverse outcome per se:
unique adverse-risk aberrations deﬁned by the ELN and the MRC were
applied in this study which were, in detail, inv(3)(q21q26), t(3;3)(q21;q26),
abnl(3q) except t(3;5)(q2125;q31q35), − 5, del(5q), add(5q), − 7, del
(7q), add(7q), t(6;9)(p23;q34), t(v;11)(v;q23) except t(9;11)(p2122;q23),
− 17 and abnl(17p),1,5 (III) AML with recurrent genetic abnormalities
according to the World Health Organization. This category includes the
recurrent abnormalities t(9;11)(p22;q23), t(6;9)(p23;q34), inv(3)(q21q26.2)/
t(3;3)(q21;q26.2), and t(1;22)(p13;q13).16 Translocation t(6;9) and inv(3)/
t(3;3) are speciﬁc adverse-risk aberrations and therefore already included in
that category. Translocation t(1;22) is a rare aberration with n= 1 patient.
Therefore, no further investigation was possible. Thus, only t(9;11)
remained as a feature of particular interest, and (IV) pure HDK with gains
of whole chromosomes (e.g., trisomies, tetrasomies), but without
additional structural aberrations or monosomies.
The distinct cytogenetic features were considered with the following
groups of complex aberrant patients: (a) HDK, (b) t(9;11), (c) complex
karyotypes with three unrelated aberrations without speciﬁc adverse-risk
aberrations, without HDK, without t(9;11) (CK3), (d) complex karyotypes with
three unrelated aberrations with at least one speciﬁc adverse-risk aberration,
without HDK, without t(9;11) (CK3+adv), (e) complex karyotypes with ⩾ 4
unrelated aberrations without speciﬁc adverse-risk aberrations, without HDK,
without t(9;11) (CK4) and (f) complex karyotypes with ⩾ 4 unrelated
aberrations with at least one speciﬁc adverse-risk aberration, without HDK,
without t(9;11) (CK4+adv). Comprehensive ﬂowcharts of the distinct groups
of complex aberrant karyotypes are depicted in Figures 1a and b.
In order to investigate the inﬂuence of an MK in the complex aberrant
situation, patients were divided into (a) patients with three unrelated
aberrations without MK (CK3−MK), (b) patients with three unrelated
aberrations with MK (CK3+MK), (c) patients with ⩾ 4 unrelated aberrations
without MK (CK4−MK) and (d) patients with ⩾ 4 unrelated aberrations with
MK (CK4+MK).
Treatment protocols
Detailed treatment descriptions of the three trials were reported
previously.13,17,18 In brief, the AML96 trial enrolled adult patients without
age restriction, whereas the AML2003 trial included patients up to 60 years
of age, and the AML60+ trial patients above the age of 60 years. Apart from
double induction chemotherapy administered to patients aged ⩽ 60 years,
all three protocols involved a risk-adapted consolidation strategy,
including HLA-compatible related or unrelated allogeneic hematopoietic
Table 1A. Patient characteristics
NK HDK t(9;11) CK3 CK4 CK+adv
n=1590 n=20 n= 10 n= 19 n= 35 n= 333
Median age (range) 56 (17–87) 60 (37–76) 40 (29–60) 56 (33–78) 56 (18–80) 61 (15–82)
Gender, male (%) 741 (47) 10 (50) 4 (40) 11 (58) 17 (49) 172 (52)
De novo AML (%) 1318 (83) 16 (80) 9 (90) 12 (63) 26 (74) 221 (66)
Median WBC (Gpt/l), range 16 (0.2–453) 12 (0.9–192) 24 (1–212) 10 (0.8–73) 7.5 (0.6–468) 4.1 (0.2–197)
Median LDH (U/l), range 427 (10–16 560) 513 (100–3058) 881 (276–2997) 261 (27–5489) 660 (93–7938) 362 (97–4160)
Table 1B. Patient characteristics
CK3+MK CK3−MK CK4+MK CK4−MK
n= 22 n=43 n=228 n= 124
Median age (range) 63 (32–75) 62 (24–82) 61 (15–82) 58 (18–81)
Gender, male (%) 12 (54) 24 (56) 118 (52) 60 (48)
De novo AML (%) 14 (64) 30 (70) 149 (65) 91 (73)
Median WBC (Gpt/l), range 7 (0.8–98) 11 (0.6–156) 4 (0.2–468) 5 (0.4–212)
Median LDH (U/l), range 406 (135–2540) 371 (27–5489) 361 (97–7938) 414 (93–3946)
Abbreviations: NK, normal karyotype (control group); HDK, hyperdiploid karyotype; CK3, complex aberrant patients with three unrelated abnormalities
without HDK, without t(9;11), and without adverse-risk abnormalities; CK4, complex aberrant patients with four or more unrelated abnormalities without HDK,
without t(9;11), and without adverse-risk abnormalities; CK+adv, complex aberrant patients with three or more aberrations of which at least one aberration
was at speciﬁc adverse risk per se with exclusion of patients with t(9;11) or HDK; CK3+MK, patients with MK and with three unrelated aberrations; CK3−MK,
patients with three unrelated aberrations without MK; CK4+MK, patients with four or more unrelated aberrations with MK; CK4−MK, patients with four or
more unrelated aberrations without MK; WBC, white blood count; LDH, lactate dehydrogenase.
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stem cell transplantation for intermediate-risk patients with a sibling donor
and adverse-risk patients with a matched donor. In the AML2003 trial,
patients were randomized up-front to undergo allogeneic hematopoietic
stem cell transplantation early after induction chemotherapy-induced
aplasia or during ﬁrst remission in deﬁned adverse-risk situations.19
Statistical analysis
Complete remission was deﬁned according to the standard consensus
criteria.20 OS was measured from the date of entering the study to the date
of event (death) or last follow-up and was reported for the whole cohort.
The Kaplan–Meier method was used to estimate the probability for OS.
Median OS were provided for all end points with 95% conﬁdence intervals
(CIs). The stratiﬁed log rank test was used for univariate comparison of OS.
The stratiﬁcation variable was the study generation.
To determine the prognostic inﬂuence of the distinct cytogenetic
groups independent of age, WBC, serum lactate dehydrogenase levels at
baseline, and type of AML (de novo AML, AML with preceding
myelodysplastic syndrome, therapy-related AML) as covariates, a stratiﬁed
multivariable Cox regression analysis for OS was performed. Stratiﬁcation
variable again was study generation. Because of its informative character,
allogeneic hematopoietic stem cell transplantation was not censored.
All statistical analyses were performed using SPSS version 19.0.1
(SPSS Inc, Chicago, IL, USA) and the R environment for statistical
computing version 2.15.3.21
RESULTS
The following cytogenetic subgroups were analyzed for their
inﬂuence on OS.
Hyperdiploid karyotype
Out of 417 patients with ⩾ 3 aberrations, 20 patients displayed
a pure HDK with a range of 49–80 chromosomes (median,
50 chromosomes) without other abnormalities. Nine patients with
HDK had 3 trisomies and 11 patients had ⩾ 4 trisomies. The most
frequent chromosomes involved in the formation of HDK were
chromosomes 8, 4, 13, 9, 10, 21 and 22 (in decreasing frequency),
present in at least more than 20% of all patients with HDK.
Additionally, tetrasomies 4, 8, 13, 14, 20 and 21, each detected in
1–2 patients, as well as pentasomies 13, 21 and 22, each detected
in one patient, were found.
The median OS for these patients was 4.6 months (95% CI,
0–17.4) (Figure 2a). The multivariable Cox regression including
age, WBC, lactate dehydrogenase and type of AML showed that
HDK was an independent prognostic factor for OS (HR 2.2; 95% CI,
1.4–3.5; P= 0.001). There was no inﬂuence of the number of
trisomies or tetrasomies on survival. Patients with three trisomies
and patients with four or more trisomies/tetrasomies had a similar
probabilities of OS (P=NS, data not shown). Furthermore, we
compared HDK patients with patients with cytogenetic adverse-
risk criteria according to the ELN/MRC classiﬁcations (Figure 2b).
OS did not differ signiﬁcantly (HR 0.6; 95% CI, 0.4–1.1; P= 0.082).
For the adverse control group (CK+adv, n= 333) no further
distinction between CK3+adv (n= 35) and CK4+adv (n= 298) was
performed since HDK patients with 3 or ⩾ 4 aberrations had
similar survival.
Additional data resulting from univariate comparisons (log rank
test) regarding OS and data resulting from multivariable Cox
regression analysis of these patients and the patients documented
below are summarized in the supplement (Supplementary Tables
S1 and S2).
t(9;11) and other WHO recurrent cytogenetic abnormalities
The following WHO recurrent cytogenetic aberrations were
detected within the complex aberrant karyotypes of the patients
analyzed: t(9;11)(p2122;q23) (n= 10 patients); t(6;9)(p23;q34)
(n = 3 patients); inv(3)(q21q26.2)/t(3;3)(q21;q26.2) (n= 9 patients)
and t(1;22)(p13;q13) (n= 1 patient). Patients with t(9;11) had an
OS similar to patients with NK with a median survival of
23 months (95% CI, 13–33.1) (Figure 2c) Interestingly, 8 out of
the 10 patients had a karyotype grouped into the CK4 cohort
and 2 patients had additional speciﬁc adverse-risk abnormalities.
Complex karyotype with three independent aberrations (CK3) vs
complex karyotype with four or more independent aberrations (CK4)
To delineate the best cutoff of complexity, we analyzed survival
data from patients with 3 or ⩾ 4 independent aberrations
(CK3, n= 19 and CK4, n= 35, respectively) who furthermore did
not have any of the adverse-risk cytogenetic aberrations, without
HDK, and without a t(9;11) (Figure 2d). CK4 patients without t(9;11)
and without adverse-risk criteria had a signiﬁcant inferior OS
as compared with the control group. Multivariable Cox regression
analysis conﬁrmed these observations for OS showing that CK4
(without adverse-risk abnormalities, without t(9;11) and without
HDK) is an independent adverse prognostic factor for OS
in comparison with NK (HR, 2.2; 95% CI, 1.5–3.3; Po0.001).
Interestingly, OS of CK3 patients without t(9;11) and the adverse-
risk criteria was reduced only slightly (HR, 1.6; 95% CI, 0.9–2.7;
P= 0.078) while there was no signiﬁcant effect for event-free
survival at all (data not shown).
Complex aberrant with three unrelated 
aberrations, n = 65 patients
minus
n = 9 HDK patients
n= 56 patients
minus
n= 35 patients with adverse risk abnormalities (CK3+adv)
n= 2 patients with t(9;11)
CK3, n = 19 patients
minus
n = 11 HDK patients
n = 341 patients
minus
n = 298 patients with adverse risk abnormalities (CK4+adv)
n = 8 patients with t(9;11)
CK4, n=35 patients
Complex aberrant with four or more unrelated
aberrations, n = 352 patients
Figure 1. The ﬂowcharts depicts all patients characterized by 3
(a) and ⩾ 4 unrelated abnormalities (b), respectively, and end with
the groups CK3 and CK4. Patients with (i) pure hyperdiploid
karyotype (HDK), (ii) adverse-risk aberrations and (iii) t(9;11) were
removed constituting distinct groups because of their strong
speciﬁc inﬂuence on outcome per se. All of the complex aberrant
patients with adverse abnormalities per se are summarized to the CK
+adv group (n= 333) resulting from n= 35 CK3+adv and n= 298
CK4+adv patients. CK3+adv consists of complex aberrant
karyotypes with three unrelated aberrations with at least one
speciﬁc adverse-risk aberration, without HDK, without t(9;11) and
CK4+adv consists of complex karyotypes with ⩾ 4 unrelated
aberrations with at least one speciﬁc adverse-risk aberration,
without HDK, without t(9;11).
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MK/unique adverse-risk aberrations
Many patients shared the cytogenetic features MK and speciﬁc
adverse-risk aberrations (Tables 2A and B and Figure 3). In the
group of patients with three aberrations, 34% patients (n= 22) had
an MK, whereas in the group of patients with ⩾ 4 aberrations, 65%
patients (n= 228) had an MK, resulting in a total of 250 patients
with MK. A total of 333 patients had speciﬁc adverse-risk
aberrations (54%, n= 35, in those patients with 3 aberrations
and 82%, n= 298 in those patients with ⩾ 4 aberrations).
The frequency of chromosome 17p abnormalities in these groups
was 11% and 38%, respectively. Of the patients belonging to the
CK3+MK group (n= 22), 64% had additional speciﬁc adverse-risk
aberrations (n= 14), whereas 95% (n= 217) of the patients
belonging to the CK4+MK group (n=228) had additional speciﬁc
adverse-risk aberrations. Because MK is often caused by monosomy
of chromosomes 5, 7 or 17, we investigated the frequencies of these
monosomies in the MK group. A total of 45% of patients with CK3+MK
as well as 66% patients with CK4+MK harbored at least one of the
above monosomies. When investigating the inﬂuence of MK, all four
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Figure 2. (a) Overall survival (OS) of patients with normal karyotype (NK) and with pure hyperdiploid karyotype (HDK) AML from the time
of diagnosis. (b) OS of patients with HDK and with complex aberrant karyotype AML with ⩾ 3 aberrations (CK+adv) of which at least one
aberration predicts an adverse risk per se, but without HDK and t(9;11) from the time of diagnosis. (c) OS of patients with NK and with complex
aberrant karyotype with t(9;11)(p21–22;q23) from the time of diagnosis. (d) OS of patients with NK, with complex aberrant karyotype with
three unrelated abnormalities but without HDK, t(9;11), and speciﬁc adverse-risk aberrations (CK3), with complex aberrant karyotype with ⩾ 4
unrelated abnormalities but without HDK, t(9;11), and speciﬁc adverse-risk aberrations (CK4). Median OS is depicted in the respective table.
Cox regression (*, hazard ratio (HR), P-value) was performed applying age, WBC, LDH and the type of AML (AML with antecedent
myelodysplastic syndrome and therapy-related AML) as co-variables. Abbreviation: LDH, lactate dehydrogenase.
Table 2A. Karyotype details in patients with 3 or ⩾ 4 aberrations
without speciﬁc consideration of other abnormalities (see also
Supplementary Figures 1A and B)
3 aberrations
n= 65
⩾ 4 aberrations
n= 352
Hyperdiploid karyotype (%) 9 (14) 11 (3)
Adverse-risk abnormality (%) 35 (54) 298 (82)
abnl(17p) (%) 7 (11) 135 (38)
Monosomal karyotype (%) 22 (34) 228 (65)
Abbreviation: abnl(17p), abnormality of chromosome 17p.
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subgroups that is, CK3−MK, CK3+MK, CK4−MK and CK4+MK, fared
worse with regard to OS than the NK control group (Figures 4a and b).
The additional inﬂuence of speciﬁc adverse-risk aberrations on
outcome was more pronounced in patients with CK4 as compared
with patients with CK3 (CK3 vs CK3+adv and CK4 vs CK4+adv;
Supplementary Figures S1a and b). Median OS in months were 9.8
(95% CI, 2.8–16.7) for CK3, 11 months (95% CI, 6–16.1) for
CK3+adv, 6.1 months (95% CI, 3.8–8.4) for CK4 and 5.4 months
(95% CI, 4.5–6.2) for CK4+adv, respectively. The hazard ratios for
the risk of death in these groups compared with NK patients in the
multivariable analysis were 1.6 for CK3 (95% CI, 0.9–2.7; P= 0.085),
1.6 for CK3+adv (95% CI, 1.1–2.3; P= 0.010), 2.3 for CK4 (95% CI,
1.6–3.3; Po0.001), and 3.3 for CK4+adv (95% CI, 2.8–3.8;
Po0.001).
DISCUSSION
Our analysis of the prognostic role of karyotype complexity
(3 vs ⩾ 4) in adult AML patients demonstrates that a higher
number of patients have ⩾ 4 (84%) aberrations than 3 (16%)
aberrations. Patients with ⩾ 4 aberrations clearly fare worse than
NK patients, which could be demonstrated for the distinct groups
CK4, CK4+adv, CK4−MK and CK4+MK. Of additional unfavorable
inﬂuence on OS was the existence of unique adverse-risk
aberrations (risk of death in comparison with NK patients for
CK4 HR, 2.3; 95% CI, 1.6–3.3 vs CK4+adv HR, 3.3; 95% CI 2.8–3.8)
or an MK (CK4−MK HR, 2.7; 95% CI, 2.2–3.3 vs CK4+MK HR, 3.3;
95% CI, 2.8–3.9). Patients with three unrelated aberrations had a
worse outcome than NK patients, too. However, the effect was less
impressive than in patients with ⩾ 4 aberrations.
The MRC data demonstrated that the level of karyotype
complexity has little impact on the outcome in patients already
having at least one of the independent abnormalities conferring
favorable or adverse risk. Additionally, the MRC reported that in
patients lacking any of these independent adverse-risk abnorm-
alities, the presence of ⩾ 4 unrelated changes was found to
provide the most informative cutoff, predicting a signiﬁcantly
inferior prognosis.5
The ELN classiﬁcation scheme allocated patients with the
recurring aberration t(9;11)(p22;q23) to the intermediate-II genetic
risk group.1 Our data conﬁrm this stratiﬁcation showing that
the t(9;11)(p21–22;q23) confers an intermediate risk even with an
accompanying complex karyotype.
Our study implies that AML patients with an HDK, speciﬁcally
those without additional monosomies or structural aberrations,
should be allocated to an adverse-risk category because of the
signiﬁcant inﬂuence on survival in comparison with NK patients
Table 2B. Karyotype details in patients with 3 or ⩾ 4 aberrations and
with a monosomal karyotype
CK3+MK CK4+MK
n= 22 n=228
Monosomal karyotype without adverse-risk
abnormality (%)
8 (36) 11 (5)
Monosomal karyotype with − 5, − 7 or − 17 (%) 10 (45) 151 (66)
Abbreviations: CK3+MK, patients with a monosomal karyotype and a
complex karyotype with three unrelated aberrations; CK4+MK, patients
with a monosomal karyotype and a complex karyotype with ⩾ 4 unrelated
aberrations.
3 aberrations
n = 56
≥4 aberrations
n = 341
Figure 3. Distribution of karyotype abnormalities in patients with
three abnormalities exclusive of an HDK and patients with ⩾ 4
abnormalities exclusive of an HDK. The karyotype abnormalities in
these patients include monosomal karyotype (MK), unique adverse-
risk risk karyotype only, unique adverse-risk risk karyotype in
combination with MK, and patients without unique adverse-risk
risk karyotype and MK. Patients with pure HDK are excluded.
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Figure 4. Overall survival (OS) from the time of diagnosis of patients with normal karyotype (NK), (a) with complex aberrant karyotype with
three unrelated abnormalities but without MK (CK3−MK), with complex aberrant karyotype with three unrelated abnormalities and MK (CK3
+MK), (b) with complex aberrant karyotype with ⩾ 4 unrelated abnormalities but without MK (CK4−MK), and with complex aberrant
karyotype with ⩾ 4 unrelated abnormalities and MK (CK4+MK). Median OS are depicted in the respective tables. Cox regression (*, hazard ratio
(HR), P-value) was performed applying age, WBC, LDH and the type of AML (AML with antecedent myelodysplastic syndrome and therapy-
related AML) as co-variables. Abbreviation: LDH, lactate dehydrogenase.
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(OS HR, 2.2; 95% CI, 1.4–3.5; P= 0.001). Recently, the impact
of hyperdiploidy in AML patients was published independently,
emphasizing the impact of this category.6 Although the authors
identiﬁed a similar, obviously non-random pattern of chromoso-
mal gains comparable to our data, they applied a different
approach by also including patients with monosomies in their
HDK group with numerical changes, whereas we addressed the
impact of pure hyperdiploidy separately without including
patients with structural abnormalities and patients with loss of
chromosomes. An analysis of the French Groupe Francophone de
Cytogenetique Hematologique investigated 38 AML patients with
high HDKs restricted to karyotypes with only high hyperdiploidy
with 49 or more chromosomes.7 Because of the inclusion of
children in the analysis by Luquet et al., a different methodology
and different statistical methods being applied, a direct compar-
ison with our results is not possible.
To date, it is not clear whether additional monosomies
or structural aberrations occur earlier in the development of
AML or whether one or the other abnormality acts as the driver or
the passenger aberration. Although gains of additional chromo-
somes appear to represent the result of clonal evolution caused by
the failure of the mitotic machinery rather than an initiating event
in AML, we suggest classifying patients with pure HDK as a distinct
category, excluding monosomies and structural abnormalities.
The introduction of the MK category by Breems et al. offered
the application of a further criterion in risk stratiﬁcation of AML
patients showing that MK identiﬁes a subset of patients with very
poor prognosis, which has been conﬁrmed by other groups.5,8,22
Our study, which was restricted to the distinct population of
complex aberrant patients, showed a relevant inﬂuence on
prognosis for the presence of an MK only in the CK4 situation
with an increased risk of death for patients with CK4+MK
as compared with patients with CK4−MK. In patients with
CK3−MK or with CK3+MK the risk of death was superimposable.
Additionally, our data conﬁrm that distinct cytogenetic features
that accompany other abnormalities have a strong inﬂuence on
outcome and must be considered independently, for example,
patients with t(9;11) conferring intermediate risk.
A consistent deﬁnition of adverse-risk complex aberrant
karyotype AML appears to be warranted. Here, we conﬁrm
a karyotype with ⩾ 4 aberrations and a pure HDK as impressive
adverse-risk abnormalities in AML. Patients with three unrelated
aberrations fare worse than NK, too, but with an OS classifying
between the ⩾ 4 patients and the intermediate NK. This is an
important ﬁnding that may help to stratify patients to individual
optimized treatment strategies and may therefore lead to
improved individual survival prognostication. Therefore, based
on our ﬁndings, we suggest the following re-classiﬁcation of
cytogenetic risk: (1) favorable risk: CBF-AML; (2) intermediate risk:
normal karyotype, t(9;11); (3) adverse risk: three aberrations
without speciﬁc adverse-risk abnormalities, without HDK; (4) very
adverse risk: ⩾ 4 aberrations, HDK, speciﬁc adverse-risk abnorm-
alities, as deﬁned by the ELN and MRC.
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